Bundibugyo Ebola Reaches 60 Zones Without a Licensed Shot

The Democratic Republic of the Congo has recorded 5,794 confirmed Bundibugyo Ebola cases and 2,786 deaths, with 60 of 151 health zones now affected. The World Health Organization logged those totals on 28 August from data through 26 August and put the death rate at 48.1 percent.

The virus is Bundibugyo, a rarer species than the Zaire ebolavirus that shaped every licensed Ebola shot and antibody drug. In the same eastern provinces that used those tools from 2018 to 2020, teams are again tracing contacts and isolating the sick, this time without a product proven to work.

Two New Zones Push the Outbreak to 60

WHO’s latest Disease Outbreak News lists 5,794 confirmed cases and 2,786 deaths inside the DRC, plus 20 cases in Uganda and one in France. Six more health zones reported cases since the previous update, including Biena, Manguredjipa and Mutwanga in North Kivu. WHO named Biena and Manguredjipa as the most recently affected.

The outbreak now covers six of the country’s 26 provinces: Ituri, North Kivu, South Kivu, Haut-Uélé, Tshopo and Bas-Uélé. Ituri has 28 of 36 health zones involved. North Kivu has 15 of 34. Bas-Uélé, the newest province on the list, began reporting on 12 August.

THE 26 AUGUST COUNT

• Confirmed cases: 5,794 in the DRC, and 5,815 when Uganda and France are included.
• Deaths: 2,786 in the DRC, a crude death rate of 48.1 percent.
• Recovered: 1,293 patients in the DRC, with 1,314 recoveries counted worldwide.
• In isolation: 843 patients, with 82.3 percent of listed contacts still being followed, according to the European Centre for Disease Prevention and Control’s 27 August update.

Ituri still carries most of the burden. A late-August UN round-up put about 85 percent of cases and 79 percent of deaths in that province. North Kivu is the second front, and it is where the newest zones sit.

Why North Kivu’s Fatality Rate Runs Higher

Beni has recorded 122 confirmed cases and 87 deaths since mid-May, according to government figures cited by Reuters and Médecins Sans Frontières. North Kivu’s death rate stood at 68 percent in that same reporting, the highest of the six affected provinces, against 48.1 percent nationwide.

Care arrives later there. Armed groups still operate along the same Beni-Butembo-Katwa belt that ran through the 2018 to 2020 epidemic, and attacks on clinics and ambulances have cut the time teams have to find the sick. Displacement camps and artisanal mining routes keep people moving, so a case found in Beni can seed a zone that had been quiet the week before.

MSF said on 28 August that it had opened a new treatment centre in Beni to shorten that delay. A 32-bed unit backed by MSF Holland had already opened at the general hospital on 10 August, according to local reporting by Actualite.cd. Bed shortages remain one of the brakes on the response.

Albert Stern, MSF’s emergency coordinator, said early diagnosis and treatment as soon as the first symptoms appear raise the chance of survival and cut spread inside families. In a virus with no approved drug, that timing is the treatment.

The Shot that Stopped Zaire Is Unproven Here

Ervebo is a single-dose vesicular stomatitis virus vaccine that displays the Zaire ebolavirus surface protein. It was used at huge scale in North Kivu and Ituri from 2018 to 2020, when more than 300,000 people were immunized, and later studies put real-world protection against Zaire disease around 84 percent from day 10. That outbreak ended with 3,470 cases and 2,287 deaths.

Bundibugyo is a different species. Kristian Andersen of Scripps Research told Chemical & Engineering News that Ervebo’s glycoprotein is about 35 percent different from Bundibugyo’s. The U.S. CDC has said animal data do not support reliable cross-protection, and on 28 May WHO advised against using Ervebo for Bundibugyo patients outside controlled research.

That advice has not been withdrawn. WHO’s immunization page still does not currently recommend Ervebo for Bundibugyo outbreaks, citing insufficient evidence that it protects against this virus. The two licensed antibody drugs, Inmazeb and Ebanga, were also built and tested against Zaire only.

The IHR Emergency Committee later asked that Ervebo be put into a randomized trial during this outbreak. The International Coordinating Group released 70,000 doses: 20,000 for that Phase 3 study and 50,000 for front-line and health workers who give informed consent. WHO said the vaccine’s effect on Bundibugyo disease and transmission remains unproven, which is why consent and a trial are required.

Antibodies Isolated After 2007 Never Became a Drug

Bundibugyo was identified in 2007 in Bundibugyo District, Uganda, where CDC figures list 149 cases and 37 deaths. A second outbreak in 2012 around Isiro in what is now Haut-Uélé produced 36 laboratory-confirmed cases and 13 confirmed deaths. WHO puts those earlier death rates at about 30 percent and 50 percent.

Survivors of the Uganda outbreak donated blood that later yielded human antibodies able to recognise several Ebola species, including Bundibugyo. James Crowe, an immunologist at Vanderbilt University Medical Center, told Nature Africa that his group isolated monoclonal antibodies that could have been developed as drugs. Manufacturing clinical-grade product and running early safety tests stalled on cost.

It’s a tragedy to me because we have the technology, we just didn’t commit the money to go to the next step.

James Crowe, immunologist, Vanderbilt University Medical Center, Nature Africa

Crowe put that next bill at $40 million and said this is where emerging-infection programmes routinely stop. Zaire, after the West Africa epidemic, attracted the money that produced Ervebo and the licensed antibodies. Bundibugyo and Sudan ebolavirus did not. The 2026 outbreak is that unpaid invoice coming due in the same hills where the Zaire playbook was written.

How This Outbreak Compares With 2014 and 2018

This is the DRC’s 17th Ebola outbreak and already its largest. It passed the 2018 to 2020 confirmed-case mark in July and is the second-largest Ebola epidemic ever recorded. UN officials said about 90 confirmed cases were logged each day on average across the first 100 days, a faster clip than West Africa in 2014 to 2016 or eastern Congo in 2018 to 2020.

EBOLA OUTBREAKS BY VIRUS AND TOOLS

West Africa remains the deadliest epidemic, with a CDC historical tally of 11,325 deaths. Secretary-General António Guterres warned on 27 August that the DRC outbreak is on a path that can still overtake that toll if weekly incidence stays near 500. He called it the fastest-growing Ebola epidemic on record and said it is growing faster and wider than the response.

Uganda showed the other outcome. Twenty confirmed cases and two deaths were tied to importations from the DRC. Kampala discharged its last patient on 16 July, declared the outbreak over on 28 July, and completed 42 days of extra monitoring on 26 August. Several health zones in northern Ituri and in South Kivu have also interrupted local transmission, according to WHO and Africa CDC. Those pauses have not bent the national curve.

Beni Adds Beds as Health Workers Keep Falling Ill

On 21 August, with the outbreak near its 100th declared day, MSF warned that communities were not getting enough support to hold the virus. Dr Javid Abdelmoneim, the group’s international president, said the epidemic was still moving faster than the response and that the work needs more than extra beds.

MSF said it was running six treatment centres and isolation units with more than 400 beds, about one third of the national total, and that more than 1,400 of its staff were on the response. Teams had admitted more than 2,000 patients, including more than 800 with confirmed Ebola. National bed capacity, UN officials said, had gone from fewer than 10 at the start to more than 1,300.

Contact follow-up rose from 9 percent in week one to 84 percent by 18 August. Even so, health authorities have said a large share of new cases still appear outside the lists of people being watched, which means chains are being found after they have already branched.

WHAT KEEPS THE VIRUS AHEAD

• Conflict: Insecurity in Ituri and North Kivu blocks surveillance teams and has included attacks on treatment centres and ambulances.
• Movement: Displacement, trade and artisanal mining corridors carry cases into new health zones and toward the Central African Republic and South Sudan borders.
• Staff losses: As of 20 August, 158 health workers had been infected and 45 had died.
• Money: The UN’s $2.13 billion humanitarian plan was 48 percent funded on 27 August, with cash on hand measured in weeks.
• Tools: No licensed vaccine or specific drug exists for Bundibugyo, so the response still rests on finding, isolating and burying the dead safely.

Tedros Adhanom Ghebreyesus, Mohamed Yakub Janabi and Jean Kaseya wrote on 25 August that the response must grow by two to three times across every pillar. They asked for protective equipment, clean water, pay on time and direct support to local groups. Delayed and fragmented financing, they wrote, is something Ebola uses.

Kisangani Begins an Unproven Vaccination Drive

On 27 August the DRC launched a vaccination campaign for frontline workers with Ervebo in Kisangani, mainly covering Tshopo, Bas-Uélé and Haut-Uélé. Those provinces are newer to the map than Ituri and North Kivu, which is where death rates have been highest and where a licensed Zaire shot was used last time.

The Democratic Republic of the Congo (#DRC) will receive Ervebo vaccines from the global Ebola virus disease vaccine stockpile for use in the current Bundibugyo virus disease outbreak.

The Ervebo vaccine is licensed and recommended for use in outbreaks of Ebola virus (previously… pic.twitter.com/LKg3GlAaO9

— World Health Organization (WHO) (@WHO) August 20, 2026

Guterres told reporters the same day that women and children were being hit especially hard and that current resources would last weeks, not months. He is appealing for the remaining $1.1 billion on the $2.13 billion plan, much of the money already in coming from the United States. “We must also overcome another virus, the virus of indifference,” he said.

HOW THE FIRST 100 DAYS RAN

1. February 2026: The virus circulates for months before confirmation as Bundibugyo, after early tests look for the more common Zaire species, according to later WHO reconstruction reported by the Associated Press.
2. 15 May 2026: The DRC government declares the country’s 17th Ebola outbreak. WHO declares a public health emergency of international concern two days later.
3. 28 July 2026: Uganda declares its outbreak over after 20 confirmed cases and two deaths, all linked to importations.
4. 20 August 2026: WHO and Africa CDC welcome 70,000 Ervebo doses from the global stockpile, split between a trial and consenting front-line staff.
5. 26 August 2026: WHO records 5,794 confirmed DRC cases, 2,786 deaths and 60 affected health zones, with Biena and Manguredjipa the newest.
6. 27 August 2026: Ervebo vaccination of health workers begins in Kisangani, and Guterres asks donors to close a $1.1 billion gap.
7. 28 August 2026: MSF says a new treatment centre is open in Beni.

CEPI has put money into Bundibugyo-specific candidates, including an IAVI rVSV construct on the same platform as Ervebo, still months from human efficacy trials. WHO is also sponsoring a treatment study that has included remdesivir and experimental antibodies. None of those products is licensed. The shot now going into arms in Kisangani is the Zaire vaccine the region already knows, used because it is in the stockpile, not because anyone has shown it stops this species in people.

Nurses in Kisangani began receiving Ervebo on 27 August, a vaccine licensed for a different virus, while a trial tries to learn whether it helps against the one that has already killed 2,786 people in the DRC.

Disclaimer: This article is news reporting on an unfolding public health emergency and is for information only. It is not medical advice, a diagnosis, or a guide to treatment, vaccination, isolation, burial practice or travel. Anyone who may have been exposed to Ebola, or who has fever or other symptoms after time in an affected health zone, should seek care from a qualified doctor or the local health authority rather than acting on this reporting. Case counts, death totals, vaccine guidance, trial status and funding figures reflect the WHO, UN, ECDC and MSF sources cited as of 29 August 2026 and will change as ministries revise their data.